Drug intelligence / Profile preview

ketamine + butorphanol

Development stage
Unknown
Lead developer
NexGen Pharmaceuticals
Modality
Small Molecules
Administration
Intravenous, Intramuscular, Subcutaneous
01

Overview

Ketamine + butorphanol is a combination of two pharmaceutical agents used primarily in veterinary medicine for sedation, anesthesia induction, and analgesia. Ketamine is a dissociative anesthetic that acts as an NMDA receptor antagonist, producing profound analgesia and anesthesia with minimal respiratory depression. Butorphanol is an opioid analgesic with mixed agonist-antagonist activity; it acts as a partial agonist at the mu-opioid receptor and a full agonist at the kappa-opioid receptor, providing both analgesic and sedative effects. This combination is commonly used for chemical immobilization of animals (especially large or exotic species) due to its rapid onset, deep sedation, reversible effects, and relatively favorable safety profile compared to other protocols[1][3][7]. The mixture allows for effective short-term immobilization with smooth induction and recovery phases.

02

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on ketamine + butorphanol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketamine + butorphanol.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call